Markus Warmuth

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.

SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

An efficient rapid system for profiling the cellular activities of molecular libraries.

A general strategy for creating "inactive-conformation" abl inhibitors.

Ba/F3 cells and their use in kinase drug discovery.

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

B-Raf kinase inhibitors for cancer treatment.

Essential role of stromally induced hedgehog signaling in B-cell malignancies.

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.

Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Hedgehog pathway activation in chronic myeloid leukemia.

Allosteric inhibition of BCR-ABL.

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

Profiling the kinome for drug discovery.

NAMPT is the cellular target of STF-31-like small-molecule probes.

Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3? Splice Site Selection through Use of a Different Branch Point.